Pricing
  1. US-listed companies
  2. HALOZYME THERAPEUTICS, INC.
  3. Financials
  4. Operating margin (%)

HALOZYME THERAPEUTICS, INC. (HALO)

Market cap
$7.9B
P/E ratio
SummaryFinancials
Period EndOperating margin (%) YoY (%)
Dec 31, 202454.3+33.43%
Dec 31, 202340.7+0.44%
Dec 31, 202240.5-34.88%
Dec 31, 202162.2+15.45%
Dec 31, 202053.9-256.27%
Dec 31, 2019-34.5-24.44%
Dec 31, 2018-45.7-278.45%
Dec 31, 201725.6-145.10%
Dec 31, 2016-56.7+179.07%
Dec 31, 2015-20.3-75.71%
Dec 31, 2014-83.7-42.99%
Dec 31, 2013-146.8+15.85%
Dec 31, 2012-126.7+258.19%
Dec 31, 2011-35.4

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat